

Amendments to the Specification

Please add the following new paragraph before paragraph [0001]:

-- This application claims the benefit of International Application No. PCT/DE03/01213, filed on April 4, 2003, which claims the benefit of Danish Application No. DE10216227.1, filed on April 5, 2002, the contents of which are incorporated in their entirety by reference herein.—

Please replace paragraph [0013] beginning on page 9, with the following rewritten paragraph:

--The significance of proteasome inhibitors as a novel therapeutic principle has experienced increased attention in recent years in particular in connection with treating cancer and inflammatory diseases (for a review, see Elliot and Ross, 2001). While their broad clinical use in humans has not yet been authorized, the pharmaceutical industry is working intensively on developing new medicaments which are based on proteasome inhibitors which are tolerated in vivo. The company "Millennium Inc." (Cambridge, Mass., USA) has developed proteasome inhibitors, in particular boric acid derivatives of dipeptides and, in this connection, particularly the compound PS-341 (Adams et al., 1999), for antiinflammatory, immunomodulatory and antineo-plastic therapies. In the rat model, the oral administration of PS-341 has an inflammation-inhibiting effect in streptococcus-induced rheumatoid arthritis and liver inflammation (Palombella et al., 1998). In the mouse model, PS-341 exhibits an antineoplastic effect against lung carcinomas and, in addition to this, has an additive effect in combination with cytostatic agents (Teicher et al., 1999). In vitro experiments demonstrate that the compound has very good activity against solid human ovarian and prostate tumor cells (Frankel et al., 2000). PS-341 is to date the only proteasome inhibitor to have been subjected to clinical trials. Phase I clinical studies on PS-341 demonstrate good bioavailability and pharmacokinetic behavior (Lightcap et al., 2000). Phase I and phase II clinical studies in patients suffering from various cancer diseases, such as hematological malignancies as solid tumors, have already been concluded. In addition to surprising therapeutic effects being achieved in different tumor patients, it is noteworthy that it was not possible to observe any dose-limiting toxicity when treating with PS-341. Millennium Inc. has presented the information in this regard in communications to the press. ~~(published under~~

<http://biz.yahoo.com/prnews/010301/neth003.html>;

<http://biz.yahoo.com/prnews/010301/neth003.html>;

http://www.mlnm.com.releases.pr052300_1.shtml;

<http://www.cancernet.nci.nih.gov/>;

<http://www3.manderson.org/leukemia/insight/letter52.html>—